<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004574</url>
  </required_header>
  <id_info>
    <org_study_id>000076</org_study_id>
    <secondary_id>00-H-0076</secondary_id>
    <nct_id>NCT00004574</nct_id>
  </id_info>
  <brief_title>Vitamin Replacement in Abetalipoproteinemia</brief_title>
  <official_title>Vitamin Replacement in Abetalipoproteinemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study will determine whether short term intravenous infusion of vitamins A and E in&#xD;
      patients with abetalipoproteinemia can reverse disease symptoms in these patients.&#xD;
      Abetalipoproteinemia is an inherited metabolic defect that prevents fat-soluble vitamins,&#xD;
      such as A and E, from being absorbed from the intestines into the bloodstream and from being&#xD;
      secreted by the liver. The deficiencies of vitamins A and E can result in severe vision&#xD;
      impairment and a gait disorder. Treatment with megadoses of these vitamins, taken by mouth,&#xD;
      may delay or arrest symptoms, but many continue to progress.&#xD;
&#xD;
      For this study, a single patient with moderately severe eye and neurological defects will be&#xD;
      given essential fatty acids and fat soluble vitamins directly through a vein (intravenously)&#xD;
      using FDA-approved replacements with a fat emulsion and multivitamins containing fat-soluble&#xD;
      vitamins. This route of administration will bypass the digestive tract, where the absorption&#xD;
      problem occurs. The infusions will be given twice a week for one month and then weekly for&#xD;
      another month. Blood tests will be done weekly to measure blood lipids (fatty acids and other&#xD;
      substances), cell counts, and vitamin levels. Eye and neurological examinations will be done&#xD;
      once a month.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fat-soluble vitamins are normally absorbed from the diet through the gastrointestinal tract&#xD;
      and incorporated into fat-rich particles called chylomicrons made in the intestinal wall.&#xD;
      Chylomicrons are secreted by the intestine into the bloodstream. In a rare lipid metabolic&#xD;
      disorder called abetalipoproteinemia, a defect in the assembly of the fat and vitamin&#xD;
      containing particles prevents the formation of chylomicrons resulting in the malabsorption of&#xD;
      fat and fat-soluble vitamins. A similar assembly defect of fat and fat-soluble vitamins&#xD;
      occurs in the liver and prevents the secretion of these particles. Severe fat-soluble vitamin&#xD;
      deficiency results even despite mega doses of oral fat-soluble vitamins. Clinically, the&#xD;
      subjects develop neurologic and ophthalmologic symptoms similar to those in Vitamin A and E&#xD;
      deficiency. This study is designed to determine whether short-term intravenous fat-soluble&#xD;
      vitamins and fat emulsion can reverse the neurologic and ophthalmologic complications of&#xD;
      fat-soluble vitamin deficiency based on noninvasive procedures routinely employed in clinical&#xD;
      practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <completion_date>May 2001</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <enrollment>1</enrollment>
  <condition>Abetalipoproteinemia</condition>
  <eligibility>
    <criteria>
      <textblock>
        None provided - protocol is intended for one patient only.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Heart, Lung and Blood Institute (NHLBI)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gotto AM, Levy RI, John K, Fredrickson DS. On the protein defect in abetalipoproteinemia. N Engl J Med. 1971 Apr 15;284(15):813-8. doi: 10.1056/NEJM197104152841503. No abstract available.</citation>
    <PMID>5549803</PMID>
  </reference>
  <reference>
    <citation>Ugele B, Kempen HJ, Kempen JM, Gebhardt R, Meijer P, Burger HJ, Princen HM. Heterogeneity of rat liver parenchyma in cholesterol 7 alpha-hydroxylase and bile acid synthesis. Biochem J. 1991 May 15;276 ( Pt 1)(Pt 1):73-7. doi: 10.1042/bj2760073.</citation>
    <PMID>2039484</PMID>
  </reference>
  <reference>
    <citation>Ikewaki K, Rader DJ, Zech LA, Brewer HB Jr. In vivo metabolism of apolipoproteins A-I and E in patients with abetalipoproteinemia: implications for the roles of apolipoproteins B and E in HDL metabolism. J Lipid Res. 1994 Oct;35(10):1809-19.</citation>
    <PMID>7852858</PMID>
  </reference>
  <verification_date>December 1999</verification_date>
  <study_first_submitted>February 17, 2000</study_first_submitted>
  <study_first_submitted_qc>December 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2002</study_first_posted>
  <last_update_submitted>March 3, 2008</last_update_submitted>
  <last_update_submitted_qc>March 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2008</last_update_posted>
  <keyword>Abetalipoproteinemia</keyword>
  <keyword>Ataxia</keyword>
  <keyword>Retinitis Pigmentosa</keyword>
  <keyword>Vitamin A</keyword>
  <keyword>Vitamin E</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abetalipoproteinemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

